Evidence map›Paper›PMID 42852166›Full record

ArticleACS omega2026

Tyr-Mpa Proximity-Induced Atypical

Xin Lu, Fangfang Yuan, Xiaojie Han, Tingting Qin, Qianqian Wang, Zengli Li, Chuanjun Ge, Wenqing Shi, Haijiao Bai, Pei Wang

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xin LuTianjin Institute for Drug Control, No. 98, Guizhou Road, Tianjin 300070, China.
Fangfang YuanTianjin Institute for Drug Control, No. 98, Guizhou Road, Tianjin 300070, China.
Xiaojie HanTianjin Institute for Drug Control, No. 98, Guizhou Road, Tianjin 300070, China.
Tingting QinTianjin Institute for Drug Control, No. 98, Guizhou Road, Tianjin 300070, China.
Qianqian WangState Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin 300350, China.
Zengli LiAnhui Anke Biotechnology (Group) Co., Ltd, No. 9 Haiguan Road, Hefei, Anhui Province 230088, China.
Chuanjun GeAnhui Anke Biotechnology (Group) Co., Ltd, No. 9 Haiguan Road, Hefei, Anhui Province 230088, China.
Wenqing ShiAnhui Anke Biotechnology (Group) Co., Ltd, No. 9 Haiguan Road, Hefei, Anhui Province 230088, China.
Haijiao BaiTianjin Institute for Drug Control, No. 98, Guizhou Road, Tianjin 300070, China.
Pei WangTianjin Institute for Drug Control, No. 98, Guizhou Road, Tianjin 300070, China.ORCID https://orcid.org/0009-0003-5268-0490

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Desmopressin, a synthetic analog of vasopressin widely used in the treatment of diabetes insipidus and bleeding disorders, is a representative disulfide-containing peptide therapeutic prepared by Fmoc-based solid-phase peptide synthesis (SPPS). Its unique sequence architecture, particularly the spatial proximity between the N-terminal mercaptopropionic acid residue Mpa(1) and the Tyr(2) residue, provides a distinct structural environment for investigating sequence-dependent side reactions during peptide manufacturing. The

Identifiers

PMID42852166
PMCPMC13647234

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.